PTPN22 and type 1 diabetes mellitus: As shown in Figure 3A, ROS production was increased following combined treatment (TNF-α+fMLP) in both the PTPN22 C1858C T1D patients (n = 6) and healthy individuals (n = 5) compared to the respective controls (unstimulated).